STADA IRBESARTAN HCT 150/12.5 irbesartan/hydrochlorothiazide 150 mg/12.5 mg tablet blister أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

stada irbesartan hct 150/12.5 irbesartan/hydrochlorothiazide 150 mg/12.5 mg tablet blister

medis pharma pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 150 mg - tablet - excipient ingredients: croscarmellose sodium; colloidal anhydrous silica; povidone; microcrystalline cellulose; magnesium stearate; hydrogenated castor oil; maize starch; lactose monohydrate - stada irbesartan hct is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

STADA IRBESARTAN HCT 300/12.5 irbesartan/hydrochlorothiazide 300 mg/12.5 mg tablet blister أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

stada irbesartan hct 300/12.5 irbesartan/hydrochlorothiazide 300 mg/12.5 mg tablet blister

medis pharma pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 300 mg - tablet - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; povidone; hydrogenated castor oil; maize starch; magnesium stearate; lactose monohydrate; croscarmellose sodium - stada irbesartan hct is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

IRBESARTAN/HCT SANDOZ 300/25 irbesartan 300 mg/hydrochlorothiazide 25 mg film-coated tablet blister pack أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

irbesartan/hct sandoz 300/25 irbesartan 300 mg/hydrochlorothiazide 25 mg film-coated tablet blister pack

sandoz pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: hypromellose; iron oxide black; macrogol 6000; colloidal anhydrous silica; lactose monohydrate; titanium dioxide; croscarmellose sodium; purified talc; microcrystalline cellulose; hyprolose; iron oxide red; magnesium stearate - irbesartan/hct sandoz is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

IRBESARTAN/HCT SANDOZ 150/12.5 irbesartan 150 mg/hydrochlorothiazide 12.5 mg film-coated tablet blister pack أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

irbesartan/hct sandoz 150/12.5 irbesartan 150 mg/hydrochlorothiazide 12.5 mg film-coated tablet blister pack

sandoz pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: purified talc; hypromellose; lactose monohydrate; iron oxide red; titanium dioxide; microcrystalline cellulose; croscarmellose sodium; iron oxide yellow; macrogol 6000; hyprolose; magnesium stearate; colloidal anhydrous silica - irbesartan/hct sandoz is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

IRBESARTAN/HCT SANDOZ 300/12.5 irbesartan 300 mg/hydrochlorothiazide 12.5 mg film-coated tablet blister pack أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

irbesartan/hct sandoz 300/12.5 irbesartan 300 mg/hydrochlorothiazide 12.5 mg film-coated tablet blister pack

sandoz pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; lactose monohydrate; hyprolose; titanium dioxide; croscarmellose sodium; colloidal anhydrous silica; macrogol 6000; purified talc; microcrystalline cellulose; iron oxide red; iron oxide yellow - irbesartan/hct sandoz is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

ZANTAC 150mg tablet أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

zantac 150mg tablet

aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 168 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; triacetin - 1. short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. treatment of gastrinoma (zollinger-ellison syndrome). 5. short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. treatment of scleroderma oesophagitis. the intravenous injection is indicated where oral treatment is inappropriate

ZANTAC 300mg tablet أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

zantac 300mg tablet

aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 336 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; triacetin - . short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. treatment of gastrinoma (zollinger-ellison syndrome). 5. short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. 6. maintenance treatment to reduce the risk of relapse of reflux oesophagitis. 7. treatment of scleroderma oesphagitis. the intravenous injection is indicated where oral treatment is inappropriate.

ZANTAC Ranitidine 150mg (as hydrochloride) effervescent tablet أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

zantac ranitidine 150mg (as hydrochloride) effervescent tablet

aspen pharmacare australia pty ltd - ranitidine hydrochloride, quantity: 168 mg (equivalent: ranitidine, qty 150 mg) - tablet, effervescent - excipient ingredients: sodium benzoate; povidone; sodium bicarbonate; monosodium dihydrogen citrate; aspartame; flavour - short term treatment of proven duodenal and gastric ulcer. maintenance treatment to reduce the risk of relapse in duodenal ulcer. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. treatment of gastrinoma (zollinger-ellison syndrome). short-term symptomatic treatment of reflux oesophagitis unresponsive to conservative anti-reflux measures and simple drug therapies such as antacids. treatment of scleroderma oesophagitis. new indications as at 2 november 1993: 1. short-term treatment of proven duodenal ulcer and gastric ulcer, including intravenous use for prophylaxis against recurrent haemorrhage. 2. maintenance treatment to reduce the risk of relapse in duodenal ulcer. 3. maintenance treatment for periods up to one year to reduce the risk of relapse in patients with documented healing of benign gastric ulcer. 4. treatment of gastrinoma (zollinger-ellison syndrome). 5. short- term symptomatic treatment of reflux oe

ABISART HCTZ 300/25 irbesartan 300 mg + hydrochlorothiazide 25 mg tablet blister pack أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

abisart hctz 300/25 irbesartan 300 mg + hydrochlorothiazide 25 mg tablet blister pack

sun pharma anz pty ltd - hydrochlorothiazide, quantity: 25 mg; irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; hypromellose; lactose monohydrate; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; iron oxide red; macrogol 4000; iron oxide black; macrogol 400 - indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

ABISART HCTZ 300/12.5 irbesartan 300 mg + hydrochlorothiazide 12.5 mg tablet blister pack أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

abisart hctz 300/12.5 irbesartan 300 mg + hydrochlorothiazide 12.5 mg tablet blister pack

sun pharma anz pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica; iron oxide yellow; hypromellose; titanium dioxide; purified talc; macrogol 4000; macrogol 400 - indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.